Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Jul 22;99(2):371-4.
doi: 10.1038/sj.bjc.6604453. Epub 2008 Jun 24.

Rapid progression of prostate cancer in men with a BRCA2 mutation

S A Narod  1 , S Neuhausen, G Vichodez, S Armel, H T Lynch, P Ghadirian, S Cummings, O Olopade, D Stoppa-Lyonnet, F Couch, T Wagner, E Warner, W D Foulkes, H Saal, J Weitzel, A Tulman, A Poll, R Nam, P Sun; Hereditary Breast Cancer Study Group; Jessica Danquah, Susan Domchek, Nadine Tung, Peter Ainsworth, Douglas Horsman, Charmaine Kim-Sing, Christine Maugard, Andrea Eisen, Mary Daly, Wendy McKinnon, Marie Wood, Claudine Isaacs, Dawna Gilchrist, Beth Karlan, Raluca Nedelcu, Wendy Meschino, Judy Garber, Barbara Pasini, Siranoush Manoukian, Christina Bellati
Affiliations

Rapid progression of prostate cancer in men with a BRCA2 mutation

S A Narod et al. Br J Cancer. .

Abstract

Men with BRCA2 mutations have been found to be at increased risk of developing prostate cancer. There is a recent report that BRCA2 carriers with prostate cancer have poorer survival than noncarrier prostate cancer patients. In this study, we compared survival of men with a BRCA2 mutation and prostate cancer with that of men with a BRCA1 mutation and prostate cancer. We obtained the age at diagnosis, age at death or current age from 182 men with prostate cancer from families with a BRCA2 mutation and from 119 men with prostate cancer from families with a BRCA1 mutation. The median survival from diagnosis was 4.0 years for men with a BRCA2 mutation vs 8.0 years for men with a BRCA1 mutation, and the difference was highly significant (P<0.01). It may be important to develop targeted chemotherapies to treat prostate cancer in men with a BRCA2 mutation.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Probability of survival after prostate cancer in men from families with BRCA1 and BRCA2 mutations (all causes of death).
Figure 2
Figure 2
Probability of survival after prostate cancer in known carriers with BRCA1 and BRCA2 (all causes of death).
See this image and copyright information in PMC

References

    1. Agalliu I, Karlines E, Kwon EM, Iwasaki LM, Diamond A, Ostrander EA, Stanford JL (2007) Rare germline mutations in the BRCA2 gene are associated with early-onset prostate cancer. Br J Cancer 97: 826–831 - PMC - PubMed
    1. Bill-Axelson A, Holmberg L, Ruutu M, Häggman M, Andersson SO, Bratell S, Spångberg A, Busch C, Nordling S, Garmo H, Palmgren J, Adami HO, Norlén BJ, Johansson JE, for the Scandinavian Prostate Cancer Group Study No. 4 (2005) Radical prostatectomy vs watchful waiting in early prostate cancer. N Engl J Med 352: 1977–1984 - PubMed
    1. Breast Cancer Linkage Consortium (1999) Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 91: 1310–1316 - PubMed
    1. Cybulski C, Górski B, Gronwald J, Huzarski T, Byrski T, Debniak TA, Wokolorczyk D, Gliniewicz B, Sikorski A, Stawicka M, Godlewski D, Kwias Z, Antczak A, Krajka K, Lauer W, Sosnowski M, Sikorska-Radek P, Bar K, Klijer R, Romuald Z, Malkiewicz B, Borkowski A, Borkowski A, Szwiec M, Posmyk M, Narod SA, Lubinski J (2008) BRCA1 mutations and prostate cancer in Poland. Eur J Cancer Prev 17: 62–66 - PubMed
    1. Kirchoff T, Kauff NN, Mitra N, Nafa K, Huang H, Palmer C, Gulati T, Wadsworth E, Donat S, Robson ME, Ellis NA, Offit K (2004) BRCA mutations and risk of prostate cancer in Ashkenazi Jews. Clin Cancer Res 10: 2918–2921 - PubMed

Publication types